A receptor-antibody hybrid hampering MET-driven metastatic spread
Abstract Background The receptor encoded by the MET oncogene and its ligand Hepatocyte Growth Factor (HGF) are at the core of the invasive-metastatic behavior. In a number of instances genetic alterations result in ligand-independent onset of malignancy (MET addiction). More frequently, ligand stimu...
Main Authors: | Chiara Modica, Cristina Basilico, Cristina Chiriaco, Nicla Borrelli, Paolo M. Comoglio, Elisa Vigna |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-01-01
|
Series: | Journal of Experimental & Clinical Cancer Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13046-020-01822-5 |
Similar Items
-
Genetic Ablation of the MET Oncogene Defines a Crucial Role of the HGF/MET Axis in Cell-Autonomous Functions Driving Tumor Dissemination
by: Chiara Modica, et al.
Published: (2023-05-01) -
Molecular Engineering Strategies Tailoring the Apoptotic Response to a MET Therapeutic Antibody
by: Chiara Modica, et al.
Published: (2020-03-01) -
HGF/c-MET Axis in Tumor Microenvironment and Metastasis Formation
by: Anna Spina, et al.
Published: (2015-01-01) -
Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma
by: Nichola Cruickshanks, et al.
Published: (2017-07-01) -
hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers
by: Ilaria Martinelli, et al.
Published: (2022-03-01)